Gabapentin enacarbil was effective in improving symptoms in patients with primary restless legs syndrome (RLS), and also was well tolerated, according to investigators reporting here at the Movement Disorder Society's (MDS) 13th International Congress of Parkinson's Disease and Movement Disorders. Lead investigator Sarah E. DeRosset MD, PhD, Glaxo Smith Kline, Research Triangle Park, North Carolina, and colleagues evaluated the effects of gabapentin enacarbil on RLS symptoms, mood, quality of life, and functioning   more »

This is an early phase study designed to test the safety of a compound. This is one of the steps necessary before conducting a large clinical trial to determine if the agent ONO-4641 is effective in MS. 　 Main Eligibility R   more »